The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics
The Polyp Prevention Trial (PPT) is a multicenter randomized controlled trial examining the effect of a low-fat (20% of total energy intake), high-fiber (18 g/1000 kcal), high-vegetable and -fruit (5-8 daily servings) dietary pattern on the recurrence of adenomatous polyps of the large bowel, precur...
Gespeichert in:
Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 1996-05, Vol.5 (5), p.375-383 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The Polyp Prevention Trial (PPT) is a multicenter randomized controlled trial examining the effect of a low-fat (20% of total
energy intake), high-fiber (18 g/1000 kcal), high-vegetable and -fruit (5-8 daily servings) dietary pattern on the recurrence
of adenomatous polyps of the large bowel, precursors of most colorectal malignancies. Eligibility criteria include one or
more adenomas removed within 6 months of randomization; complete nonsurgical polyp removal and complete colonic examination
to the cecum at the qualifying colonoscopy: age 35 years of more; no history of colorectal cancer, inflammatory bowel disease,
or large bowel resection; and satisfactory completion of a food frequency questionnaire and 4-day food record. Of approximately
38,277 potential participants with one or more polyps recently resected, investigators at eight clinical centers randomized
2,079 (5.4%; 1,037 in the intervention and 1,042 in the control arm) between June 1991 and January 1994, making the PPT the
largest adenoma recurrence trial ever conducted. Of PPT participants, 35% are women and 10% are minorities. At study entry,
participants averaged 61.4 years of age; 14% of them smoked, and 22% used aspirin. At the baseline colonoscopy, 35% of participants
had two or more adenomas, and 29% had at least one large (> of = 1 cm) adenoma. Demographic, behavioral, dietary, and clinical
characteristics are comparable across the two study arms. Participants have repeat colonoscopies after 1 (T(1)) and 4 (T(4))
years of follow-up. The primary end point is adenoma recurrence; secondary end points include number, size, location, and
histology of adenomas. All resected lesions are reviewed centrally by gastrointestinal pathologists. The trial provides 90%
power to detect a reduction of 24% in the annual adenoma recurrence rate. The primary analytic period, on which sample size
calculations were based is 3 years (T(1) to T(4)), which permits a 1-year lag time for the intervention to work and allows
a more definitive clearing of lesions at T(1), given that at least 10-15% of polyps may be missed at baseline. The final (T(4))
colonoscopies are expected to be completed in early 1998. |
---|---|
ISSN: | 1055-9965 1538-7755 |